The FDA, ICH S7B guidelines set out a non-clinical testing strategy to assess the effects of pharmaceuticals on ventricular repolarisation and proarrhythmic risk. The most common mechanism for this is inhibition of the delayed rectified potassium current IKr. The human ether-à-go-go-related gene (hERG) encodes the potassium ion channel responsible for IKr.